Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Other Operating Expenses (2020 - 2023)

Goldenwell Biotech's Other Operating Expenses history spans 3 years, with the latest figure at -$68634.0 for Q1 2023.

  • For Q1 2023, Other Operating Expenses changed N/A year-over-year to -$68634.0; the TTM value through Dec 2023 reached -$68634.0, changed N/A, while the annual FY2021 figure was -$253310.0, N/A changed from the prior year.
  • Other Operating Expenses reached -$68634.0 in Q1 2023 per GWLL's latest filing, up from -$253310.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$292.0 in Q2 2020 to a low of -$253310.0 in Q4 2021.
  • Average Other Operating Expenses over 3 years is -$92959.2, with a median of -$68634.0 recorded in 2023.
  • The largest YoY upside for Other Operating Expenses was 16632.19% in 2021 against a maximum downside of 16632.19% in 2021.
  • A 3-year view of Other Operating Expenses shows it stood at -$292.0 in 2020, then tumbled by 86650.0% to -$253310.0 in 2021, then surged by 72.91% to -$68634.0 in 2023.
  • Per Business Quant, the three most recent readings for GWLL's Other Operating Expenses are -$68634.0 (Q1 2023), -$253310.0 (Q4 2021), and -$48858.0 (Q2 2021).